IMC008 / Immunofoco - LARVOL DELTA

Orphan Designation: Treatment of pancreatic cancer (FDA) - Date Designated: 08/28/2023

Orphan drug • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

up to date! This cell therapy product has been granted Orphan Drug Designation by the US FDA [Google translation] (pharnexcloud.com) - "...IMF...announced that its self-developed new generation of autologous CAR-T product IMC008 based on the company's SNR technology platform has been approved by the US Food and Drug Administration. Orphan Drug designation for the treatment of patients with gastric cancer...IMC008 is a new generation of autologous CAR-T product based on the synthetic natural killer receptor (SNR) technology platform."

Orphan drug • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of IMC008 for Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Changhai Hospital

Metastases • New P1 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18